CORRELATION OF SERUM VISFATIN LEVELS WITH DYSLIPIDEMIA IN OBESE BALB/C MICE
Keywords:
Visfatin, Obesity, Adipocytokines, dyslipidemia, Albino miceAbstract
Background: Visceral adipose tissues secrete several adipocytokines that modulate on their own way the extreme obesity, diabetes, dyslipidemia, atherosclerosis and inflammation. Visfatin is newly identified adipocytokine that is released by visceral adipose tissue. Its levels markedly increase during development of obesity. The aim of this study was to determine the levels of visfatin and its association with dyslipidemia in obese albino mice. Methods: It was a quasi experimental study. Sixty (60) Balb/c strain albino mice were divided into two groups of 30 each. Group I was taken as control non obese mice while Group II animals were fed high fat/high carbohydrate diet. Blood samples were collected to measure Total Cholesterol (TC), Triglycerides (TG), High Density Lipoprotein (HDL-C), Low Density Lipoprotein (LDL-C), Very Low Density Lipoprotein (VLDL-C) and visfatin levels. Results: There was significant correlation among different classes of lipids with increasing visfatin levels in diet induced obese mice (p<0.05). TC, TG, LDL and VLDL showed significant elevation in serum levels (5.94±1.18 mmol/L, 2.92±0.15 mmol/L, 3.91±0.56 mmol/L, 1.56±0.31 mmol/L respectively) against controls (3.1±0.40 mmol/L, 1.62±0.01 mmol/L, 1.82±0.432 mmol/L, 0.60±0.13 mmol/L correspondingly). Pearson’s correlation coefficient between rising serum visfatin and various classes of lipids showed strong positive correlation between visfatin and TC, TG, LDL, and VLDL, while negative correlation with serum HDL levels (p<0.05). Conclusion: Increased serum visfatin levels are strongly associated with obesity and dyslipidemia.
Keywords: Visfatin, obesity, adipocytokines, dyslipidemia
Pak J Physiol 2018;14(1):27–9
Downloads
References
2. Lu LF, Yang SS, Wang CP, Hug WC, Yu TH, Chiu CA, et al. Elevated visfatin, Pre B colony enhancing factor plasma concentration in ischemic strokes. J Stroke Cerebrovasc Dis 2009;18:354–9.
3. Antuna-Puente B, Feve B, Fellahi S, Bastard J. Adipokines: The missing link between insulin resistance and obesity. Diabetes Metab 2008;34(1):2–11.
4. Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT, et al. The relationship between visfatin levels and anthropometric and metabolism parameters: association with cholesterol levels in women. Metabolism 2007;56:1216–20.
5. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in over weight/obesity, Type 2 Diabetes Mellitus, Insulin resistance, Metabolic syndrome in cardiovascular diseases; A meta analysis and systemic review. Diabetese Metab Res Rev 2011;27:515–27.
6. Atacani I, Parlak A, Aydogan U, Sari O, Gok DE, Cayci T, et al. The effect of valsartan treatment on visfatin levels and lipid profiles in newly diagnosed hypertensives. Turk J Med Sci 2013;43:57–62.
7. Adeghate E. Visfatin: Structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008;15:1851–62.
8. Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high- density lipoprotein cholesterol. Diabetese Res Clin Pract 2008;79:412–8.
9. Kolsgaard ML, Wangenseen T, Brunborg C, Joner H, Holven KB, Halvorsen B, et al. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest 2009;69:858–64.
10. Araki S, Dobashi K, Kubo K, Kawagoi R, Yammoto Y. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008;16:384–8.
11. Karrasch T, Leszczak S, Bala M, Ober I, Martin J, Schmid A, et al. Short term regulation of visfatin release in vivo by oral lipid ingestion and in vitro by fatty acid stimulation. Exp Clin Endocrinol Diabetese 2014;122:126–34.
12. Divkovic D, Selthofer-Relatic K, Cosic A, Drenjancevic I, Kristek J, Radic R. Serum visfatin concentration in eutrophic and overweight/obese male children in early child hood. Period Biol 2014;116(2):191–6.
13. Taskesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012;4(2):76–81.
14. Stastny J, Bienertova-Vasku J, Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr 2012;6(2):120–4.
15. EL-Shafey EM, El-Naggar GF, Al-Bedewy MM, El Sorogi H, Is there a relationship between Visfatin levels and type 2 diabetes mellitus in obese and non obese patients? J Diabetes Metab 2012;S11:001.
16. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinal Metab 2004;89:2548–56.
17. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, et al. Sibutramine and L-carnitine compared to Sibutramine alone on insulin resistance in diabetic patients. Intern Med 2010;49:1717–25.
18. Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM, et al. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol 2007;157:437–42.
Downloads
Published
How to Cite
Issue
Section
License
Pakistan Journal of Physiology, Pak J Physiol, PJP is FREE for research and academic purposes. It can be freely downloaded and stored, printed, presented, cited and quoted with full reference of, and acknowledgement to the PJP.
